Curis, Inc. (NASDAQ:CRIS) traded up 8.7% on Tuesday . The stock traded as high as $0.76 and last traded at $0.75. 2,556,147 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 1,688,473 shares. The stock had previously closed at $0.69.

Several equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Guggenheim assumed coverage on shares of Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 price objective on the stock. Three research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $6.50.

The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $122.89, a price-to-earnings ratio of -1.78 and a beta of 1.63.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The company had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. The company’s revenue was up 38.6% on a year-over-year basis. research analysts expect that Curis, Inc. will post -0.41 earnings per share for the current fiscal year.

In related news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 115,890 shares in the company, valued at approximately $122,843.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.07% of the company’s stock.

Several large investors have recently modified their holdings of CRIS. FNY Partners Fund LP raised its holdings in shares of Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 52,500 shares during the period. OxFORD Asset Management LLP acquired a new stake in shares of Curis during the second quarter worth $115,000. Voya Investment Management LLC grew its position in Curis by 21.8% in the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares in the last quarter. Alliancebernstein L.P. grew its position in Curis by 338.7% in the second quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 64,700 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Curis by 514.0% in the fourth quarter. SG Americas Securities LLC now owns 269,128 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 225,295 shares in the last quarter. Institutional investors and hedge funds own 55.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/curis-cris-trading-8-7-higher/1823588.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.